Aminoglycosides are selectively active against gram negative bacteria through inhibition of protein synthesis; moreover, those are given parenterally or topically because they are poorly absorbed from the gastrointestinal tract, therefore are given parenterally or topically. Nephrotoxicity and ototoxicity are the most common side effects associated with aminoglycosides therapy. As the resistance developed in most of the bacteria that open the door to use either most toxic combination therapy of present aminoglycosides with other antibiotics such as beta lactams or vancomycin with which they exert a synergistic effect or to discover next generation aminoglycosides, without toxicities. For the discovery of next generation aminoglycosides, a successful step passes through identification of one structure with molecular formula C25H48N6O10 and 592.68 molecular wight from 490 analogous of sisomicin with absence of 3’-OH and 4’-OH groups and named as “ACHN-490” or “Plazomicin” by Achaogen. Plazomicin showed activity against Enterobacteriaceae (EC), Multi drug resistant Enterobacteriaceae (MDR-EC), Aminoglycoside resistant Enterobacteriaceae (AR-EC), Carbapenem resistant Enterobacteriaceae (CR-EC), Colistin resistant (CR-CRE), Tigecycline resistant (TR-EC). Lack of nephrotoxicity or ototoxicity associated with plazomicin; make it drug of future in next generation aminoglycosides. In this review, I am trying to underlying discovery and development of plazomicin as newer antibiotic.
Cite this article:
Akhilesh Gupta. Plazomicin: A step toward next generation aminoglycosides. Review. Asian J. Res. Pharm. Sci. 2017; 7(3):173-180. doi: 10.5958/2231-5659.2017.00027.3